The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension
Summary In this study, efficacy of the angiotensin II type 1 receptor blocker telmisartan given as monotherapy was compared with that of perindopril monotherapy in patients with mild‐to‐moderate hypertension. After a 2‐week, single‐blind, placebo run‐in period, 60 patients were randomised to double‐...
Saved in:
Published in | International journal of clinical practice (Esher) Vol. 58; no. s145; pp. 50 - 54 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.12.2004
Hindawi Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
In this study, efficacy of the angiotensin II type 1 receptor blocker telmisartan given as monotherapy was compared with that of perindopril monotherapy in patients with mild‐to‐moderate hypertension. After a 2‐week, single‐blind, placebo run‐in period, 60 patients were randomised to double‐blind, once‐daily treatment with telmisartan 80 mg or perindopril 4 mg for 6 weeks. Clinic and ambulatory blood pressure measurements and clinical laboratory evaluation were performed at the end of the placebo run‐in and active treatment phases. Both telmisartan and perindopril significantly (p < 0.0001) reduced clinic systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared with baseline values. Also, both drugs significantly (p < 0.0001) reduced 24‐h mean ambulatory SBP and DBP compared with baseline. Comparison of the mean hourly antihypertensive activities showed that the reduction in mean ambulatory DBP for the last 8 h of the dosing interval was significantly greater (p < 0.05) in telmisartan‐treated patients. A 24‐h mean DBP of <85 mmHg was observed in 66.6% of the telmisartan‐treated patients but in only 46.6% of the perindopril‐treated patients (p < 0.05). It is concluded that telmisartan and perindopril both produce significant reductions in clinic SBP and DBP, but the mean reduction in ambulatory DBP during the last 8 h of the dosing interval is greater in patients treated with telmisartan. |
---|---|
Bibliography: | istex:1650AF82A41F445CFD803F107317F3FF874942D8 ark:/67375/WNG-7PVCG3ZB-V ArticleID:IJCP411 |
ISSN: | 1368-5031 1368-504X 1742-1241 |
DOI: | 10.1111/j.1742-1241.2004.00411.x |